← Back to headlines
FDA Grants Fast Track Designation to Kymera Therapeutics' KT-621
The U.S. Food and Drug Administration has granted Fast Track designation to Kymera Therapeutics, Inc.'s KT-621 for the treatment of eosinophilic asthma. This designation aims to expedite the development and review of drugs for serious conditions.
24 Apr, 13:41 — 24 Apr, 13:41
Sources
Showing 1 of 1 sources
Related Stories
Cyclospora Outbreak Linked to Iceberg Lettuce Expands to Three Additional States
2h ago
Australian Woman Gives Birth to Twins Fathered by Two Different Men
4h ago
U.S. FDA Approves Landmark Pancreatic Cancer Drug With Improved Survival Rates
8h ago
West Nile Virus Outbreaks Spread Across Greece and North Macedonia
9h ago